Damora Therapeutics, Inc.
DMRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Damora Therapeutics, Inc. focuses on Biotechnology services and products. Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The $1.53B market capitalization puts DMRA squarely in small-cap range for its industry. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Market Cap
$1.53B
Beta
1.51
P/E (TTM)
—
P/E (Fwd)
-11.01
EPS (TTM)
$-2.68
EPS (Fwd)
$-2.26
ROE
-89.5%
ROA
-14.7%
Cash
$532.9M
Total Debt
$0
Free CF
-$8.7M
52W Change
677.5%
Annual Financials
Cash vs Debt
Damora Therapeutics, Inc. reports $532.9M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$8.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -89.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, DMRA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Damora Therapeutics, Inc. and its sector.